Pembrolizumab in a
Pembrolizumab in a
About this item
Full title
Pembrolizumab in a
Author / Creator
Publisher
Future Medicine Ltd
Journal title
Immunotherapy, 2016-06, Vol.8 (6), p.687-692
Language
English
Formats
Publication information
Publisher
Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with
-mutant metastatic melanoma who discontinued treatment with ipilimumab due to treatment-related grade 3 colitis an...
Alternative Titles
Full title
Pembrolizumab in a
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_futurescience_futuremedicine_10_2217_imt_2015_0025
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_futurescience_futuremedicine_10_2217_imt_2015_0025
Other Identifiers
ISSN
1750-743X
E-ISSN
1750-7448
DOI
10.2217/imt-2015-0025
How to access this item
Log in as a Library member
